Europe, Middle East, And Africa Point-Of-Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), By End Use (Clinics, Home), By Country, And Segment Forecasts, 2024 - 2030

Report Overview

The Europe, Middle East, and Africa (EMEA) point-of-care (PoC) diagnostics market size was valued at USD 13.00 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2030. The growing geriatric population coupled with high incidence rates of chronic diseases has primarily fostered market growth. Conditions such as diabetes, cardiovascular diseases, and infectious diseases including HIV, tuberculosis, and influenza have increased the demand for rapid and accurate diagnostic solutions. The ability of PoC diagnostics to provide immediate results at the patient’s location has made them indispensable in managing these health conditions effectively. Moreover, government initiatives in an attempt to shorten hospital stays, the establishment of outpatient care models, and improvement of healthcare infrastructure with beneficial insurance policies are expected to boost the demand for PoC diagnostics.

In addition, technological advancements in microfluidics, molecular diagnostics, and immunoassays have enhanced the accuracy, speed, and ease of use of PoC devices. These advancements have improved patient outcomes and expanded the range of tests including glucose monitoring, infectious disease testing, and cardiac marker detection. The integration of digital health technologies, such as Electronic Medical Records (EMR) and telemedicine, has further boosted the adoption of PoC diagnostics by enabling seamless data sharing and remote patient monitoring.

Furthermore, government initiatives and supportive policies have been instrumental in driving the growth of the PoC diagnostics market in the EMEA region. Governments have increasingly recognized the importance of early disease detection and management in reducing healthcare costs and improving public health outcomes. As a result, they have implemented various programs to promote the use of PoC diagnostics, including funding for research and development, subsidies for healthcare providers, and public awareness campaigns.

Product Insights

Glucose testing dominated with a market share of 32.7% in 2023. The market growth can be attributed to the rising prevalence of diabetes with an increasing number of individuals requiring regular glucose monitoring to manage their condition effectively. This has led to a higher demand for PoC glucose testing products, such as glucose meters, continuous glucose monitoring (CGM) systems, and associated consumables including testing strips and lancets. Moreover, innovations such as minimally invasive CGM systems and smart glucose meters integrated with digital health platforms have made glucose testing more accessible and efficient. These advancements help patients monitor their glucose levels in real-time and make informed decisions about their health.

Cancer markers are projected to grow at the fastest CAGR during the forecast period owing to the rising incidence of cancer which necessitated early and accurate detection methods to improve patient outcomes. These tests, which include products such as immunoassays, molecular diagnostics, and biosensors, have become essential tools in the early diagnosis and monitoring of various cancers. Such products enable healthcare providers to detect cancer at an early stage, leading to timely treatment and a better prognosis. Furthermore, innovations such as next-generation sequencing (NGS) and liquid biopsy techniques have revolutionized cancer diagnostics by providing non-invasive, highly accurate, and rapid testing options.

End Use Insights

Clinics held the largest market share in 2023 due to the increasing prevalence of chronic and infectious diseases, requiring rapid and accurate diagnostic solutions. Clinics, often being the first point of contact for patients, require efficient PoC diagnostics to provide timely care and improve patient outcomes. Moreover, this segment is expected to maintain its market position throughout the forecast period with the emergence of rapid clinics. These clinics facilitate primary healthcare at low costs and have an extensive (24/7) duration of operation. In addition, governments in the EMEA region have streamlined the approval processes for new diagnostic devices, facilitating their faster entry into the market.

Home healthcare facilities are projected to grow at a CAGR of 7.4% over the forecast period. The increasing incidence of chronic diseases such as diabetes, cardiovascular diseases, and respiratory conditions is one of the primary market drivers. These conditions often require regular monitoring, and PoC diagnostics provide a convenient solution for patients to manage their health from the comfort of their homes. Additionally, innovations in portable and user-friendly diagnostic devices, such as glucose monitors, blood pressure monitors, and home testing kits for infectious diseases, have made it easier for patients to conduct tests independently. Furthermore, the integration of digital health technologies, including mobile apps and telemedicine platforms, has further boosted the market with real-time data sharing between patients and healthcare providers.

Regional Insights

The Germany point-of-care diagnostics market accounted for 15.7% of the share in 2023. The country witnessed an increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and respiratory conditions that require timely and accurate results. The convenience and immediacy of PoC testing enable healthcare providers to make quick decisions, improving patient outcomes and reducing the burden on traditional laboratory services. Moreover, Germany’s strong healthcare infrastructure and supportive government policies have implemented various initiatives to promote the use of PoC diagnostics, including funding for research and development, subsidies for healthcare providers, and public awareness campaigns.

UK Point-Of-Care Diagnostics Market Trends

The UK point-of-care diagnostics market is expected to emerge as the fastest-growing country during the forecast period. The market is driven by technological advancements such as microfluidics, biosensors, and molecular diagnostics that have improved the accuracy, speed, and ease of use of these devices. These have significantly catered to the rising prevalence of chronic conditions.

South Africa Point-Of-Care Diagnostics Market Trends

The point-of-care diagnostics market in South Africa in 2023 was driven by the rising prevalence of infectious diseases, including HIV and tuberculosis. The country’s healthcare system has increasingly focused on improving access to diagnostic services, especially in rural and underserved areas, which has led to a higher adoption of point-of-care diagnostics. Additionally, the increasing geriatric population, which is more susceptible to chronic diseases, has further fueled the demand for PoC diagnostics.

UAE Point-Of-Care Diagnostics Market Trends

The UAE point-of-care diagnostics market is expected to grow at a CAGR of 4.4% during the forecast period owing to the increasing shift towards decentralizing healthcare services, which has led to a higher adoption of point-of-care diagnostics. This decentralization allows quicker clinical decision-making and improved patient outcomes by enabling healthcare providers to conduct tests at the patient’s bedside. In addition, technological advancements have played a crucial role, with innovations in portable diagnostic devices such as handheld analyzers and lateral flow assays enhancing the accuracy and speed of diagnostics.

Key Companies & Market Share Insights

Key players in the EMEA PoC diagnostics market include F. Hoffmann-La Roche Ltd, QIAGEN, Danaher Corporation, and others. These companies have been involved in strategic alliances with biotechnology-based companies and diagnostics laboratories to enhance the usage of PoC diagnostic tests. Furthermore, huge R&D investments by companies for the development of novel tests coupled with new product launches are also expected to fuel market growth over the forecast period.

• Abbott is a prominent player in the healthcare industry, known for its diverse range of science-based nutritional products, diagnostic tools, branded generic pharmaceuticals, and diabetes and vascular devices. The company operates with a strong commitment to innovation and research, continuously developing solutions to address the evolving healthcare needs of the population.

Recent Development

• In July 2024, EKF Diagnostics Holdings plc launched the Biosen C-Line, an advanced iteration of its leading rapid benchtop glucose and lactate analyzer. The Biosen C-Line provides a secure and fast method for connecting POC devices to hospital and laboratory IT systems, ensuring that patient results are quickly and securely accessible to clinicians

• In June 2023, Sysmex Corporation launched “the System”, a testing system, in Europe. It detects bacteria absence or presence and evaluates antimicrobials effectiveness by using patient’s, suspected of having urinary tract infections (UTIs), urine samples

• In June 2022, F. Hoffmann-La Roche Ltd launched the BenchMark ULTRA PLUS tissue staining system, featuring optimized workflow, testing efficiency, and environmentally sustainable attributes. The system is designed to empower pathologists to deliver high-quality, time-sensitive results to doctors and patients.

• In May 2022, miDiagnostics, a Belgium-based company, launched a COVID-19 PCR test. It is CE-IVD-certified ultra-fast for decentralized testing. The test is accessible throughout Europe and other nations that recognizes CE-IVD marking, offering a vital tool for managing situations.

Europe, Middle East, and Africa Point-Of-Care Diagnostics Market Report Scope

Europe, Middle East, And Africa Point-Of-Care Diagnostics Market Report Segmentation

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the Europe, Middle East, and Africa Point-Of-Care Diagnostics market report based on product, end use, and region.

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Glucose Testing

  • Hb1Ac Testing

  • Coagulation Testing

  • Fertility/Pregnancy

  • Infectious Disease

    • HIV POC

    • Clostridium Difficile POC

    • HBV POC

    • Pneumonia or Streptococcus Associated Infections

    • Respiratory Syncytial Virus (RSV) POC

    • HPV POC

    • Influenza/Flu POC

    • HCV POC

    • MRSA POC

    • TB and Drug-resistant TB POC

    • HSV POC

    • COVID-19

    • Other Infectious Diseases

  • Cardiac Markers

  • Thyroid Stimulating Hormone

  • Hematology

  • Primary Care Systems

  • Decentralized Clinical Chemistry

  • Feces

  • Lipid Testing

  • Cancer Marker

  • Blood Gas/Electrolytes

  • Ambulatory Chemistry

  • Drug of Abuse (DOA) Testing

  • Autoimmune Diseases

  • Urinalysis/Nephrology

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Clinics

    • Pharmacy & Retail Clinics

    • Physician Office

    • Urgent Care Clinics

  • Hospitals

  • Home

  • Assisted Living Healthcare Facilities

  • Laboratory

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait